TW202317534A - 用於治療神經退化性疾病之含羧酸吖丁啶基化合物 - Google Patents
用於治療神經退化性疾病之含羧酸吖丁啶基化合物 Download PDFInfo
- Publication number
- TW202317534A TW202317534A TW111122266A TW111122266A TW202317534A TW 202317534 A TW202317534 A TW 202317534A TW 111122266 A TW111122266 A TW 111122266A TW 111122266 A TW111122266 A TW 111122266A TW 202317534 A TW202317534 A TW 202317534A
- Authority
- TW
- Taiwan
- Prior art keywords
- azetidin
- mmol
- piperidine
- carboxylic acid
- compound
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163211313P | 2021-06-16 | 2021-06-16 | |
| US63/211,313 | 2021-06-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TW202317534A true TW202317534A (zh) | 2023-05-01 |
Family
ID=82595041
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW111122266A TW202317534A (zh) | 2021-06-16 | 2022-06-15 | 用於治療神經退化性疾病之含羧酸吖丁啶基化合物 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US11919879B2 (https=) |
| EP (1) | EP4355729A1 (https=) |
| JP (1) | JP2024522718A (https=) |
| KR (1) | KR20240021883A (https=) |
| CN (1) | CN117500785A (https=) |
| AR (1) | AR126159A1 (https=) |
| AU (1) | AU2022291768A1 (https=) |
| BR (1) | BR112023023420A2 (https=) |
| CA (1) | CA3217423A1 (https=) |
| IL (1) | IL308122A (https=) |
| MX (1) | MX2023014197A (https=) |
| TW (1) | TW202317534A (https=) |
| WO (1) | WO2022266162A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11919879B2 (en) * | 2021-06-16 | 2024-03-05 | Celgene Corporation | Carboxylic acid containing azetidinyl compounds for the treatment of neurodegenerative diseases |
| KR20250114133A (ko) * | 2022-12-16 | 2025-07-28 | 셀진 코포레이션 | S1p5의 조정제로서의 헤테로시클릭 화합물 |
| KR20260034665A (ko) | 2023-06-30 | 2026-03-11 | 사노피 | 치환된 환형 화합물 및 페닐케톤뇨증 및 기타 아미노산뇨증의 치료 방법 |
| WO2026008750A1 (en) | 2024-07-05 | 2026-01-08 | Syngenta Crop Protection Ag | Novel carboxamide compounds |
Family Cites Families (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NO167087C (no) | 1985-10-25 | 1991-10-02 | Secr Defence Brit | Fremgangsmaate for fremstilling av en nitratester. |
| US5561227A (en) | 1991-07-23 | 1996-10-01 | Schering Corporation | Process for the stereospecific synthesis of azetidinones |
| LT3300B (en) | 1992-12-23 | 1995-06-26 | Schering Corp | Combination of a cholesterol biosynhtesis inhibitor and a beta- lactam cholesterol absorbtion inhibitor |
| RU2175324C2 (ru) | 1995-09-01 | 2001-10-27 | Фармация Энд Апджон Компани | Фенилоксазолидиноны, имеющие с-с-связь с 4-8-членными гетероциклическими кольцами |
| WO2000005214A2 (en) | 1998-07-24 | 2000-02-03 | Pfizer Inc. | Isoquinolines as urokinase inhibitors |
| WO2003018549A2 (en) | 2001-08-30 | 2003-03-06 | Chemocentryx, Inc. | Bicyclic compounds as inhibitors of chemokine binding to us28 |
| RS20050019A (sr) | 2002-07-12 | 2007-09-21 | Sanofi - Aventis Pharma Deutschland Gmbh., | Heterociklično supstituisani benzoilkarbamidi,postupak za njihovu proizvodnju i njihova primena kao leka |
| JP4516430B2 (ja) | 2002-12-20 | 2010-08-04 | メルク・シャープ・エンド・ドーム・コーポレイション | １−（アミノ）インダン並びに（１，２−ジヒドロ−３−アミノ）−ベンゾフラン、ベンゾチオフェン及びインドール |
| CA2509406C (en) | 2002-12-23 | 2012-07-03 | Janssen Pharmaceutica N.V. | Substituted 1-piperidin-4-yl-4-azetidin-3-yl-piperazine derivatives and their use as neurokinin antagonists |
| GB0510204D0 (en) | 2005-05-19 | 2005-06-22 | Chroma Therapeutics Ltd | Enzyme inhibitors |
| JP2009530389A (ja) * | 2006-03-21 | 2009-08-27 | エピックス デラウェア， インコーポレイテッド | Ｓ１ｐ受容体調節化合物及びその使用 |
| US8962825B2 (en) | 2006-10-30 | 2015-02-24 | Glaxosmithkline Intellectual Property Development Limited | Hydroxamates as inhibitors of histone deacetylase |
| US20090137549A1 (en) | 2006-11-09 | 2009-05-28 | Paul John Edward | Novel compounds useful for the treatment of degenerative & inflamatory diseases |
| WO2010056788A1 (en) | 2008-11-17 | 2010-05-20 | Merck Sharp & Dohme Corp. | Anti-hypercholesterolemic compounds |
| ES2427917T3 (es) | 2009-02-10 | 2013-11-04 | Astrazeneca Ab | Derivados de triazolo [4,3-b] piridazina y sus usos para el cáncer de próstata |
| WO2011036889A1 (ja) | 2009-09-25 | 2011-03-31 | 武田薬品工業株式会社 | 複素環化合物 |
| GB201002563D0 (en) | 2010-02-15 | 2010-03-31 | Cambridge Entpr Ltd | Compounds |
| MA34300B1 (fr) | 2010-05-13 | 2013-06-01 | Amgen Inc | Composés azotés hétérocycliques convenant comme inhibiteurs de la pde10 |
| US8946230B2 (en) | 2010-05-13 | 2015-02-03 | Amgen Inc. | Aryl- and heteroaryl- nitrogen-heterocyclic compounds as PDE10 inhibitors |
| WO2012082947A1 (en) | 2010-12-16 | 2012-06-21 | Irm Llc | Compounds and compositions as tgr5 agonists |
| EP2545964A1 (en) | 2011-07-13 | 2013-01-16 | Phenex Pharmaceuticals AG | Novel FXR (NR1H4) binding and activity modulating compounds |
| WO2013169622A1 (en) | 2012-05-09 | 2013-11-14 | Zoetis Llc | Azetidine derivatives as antiparasitic agents |
| TW201408652A (zh) | 2012-07-11 | 2014-03-01 | Hoffmann La Roche | 作爲ＲＯＲｃ調節劑之芳基磺內醯胺衍生物 |
| BR112015010649A2 (pt) | 2012-11-16 | 2017-07-11 | Bristol Myers Squibb Co | moduladores de gpr40 à base de pirrolidina |
| MX2016004934A (es) | 2013-10-17 | 2016-12-20 | Abbvie Deutschland | Derivados de aminotetralina y aminoindano, composiciones farmaceuticas que los contienen, y su uso en terapia. |
| CA2934700A1 (en) | 2014-01-06 | 2015-07-09 | Rhizen Pharmaceuticals Sa | Glutaminase inhibitors |
| FR3017867A1 (fr) * | 2014-02-21 | 2015-08-28 | Inventiva | Nouveaux composes de type phenylazetidine carboxylate ou carboxamide |
| DK3140296T3 (en) | 2014-05-07 | 2018-07-23 | Bristol Myers Squibb Co | PYRROLIDIN GPR40 MODULATORS FOR TREATMENT OF DISEASES SUCH AS DIABETES |
| EP3191453B1 (en) | 2014-09-09 | 2019-10-23 | Bristol-Myers Squibb Company | Phenyl-(aza)cycloalkyl carboxylic acid gpr120 modulators |
| WO2017019540A2 (en) | 2015-07-24 | 2017-02-02 | Yale University | Inhibitors of n-linked glycosylation and methods using same |
| HRP20230201T1 (hr) | 2015-10-12 | 2023-03-31 | Chong Kun Dang Pharmaceutical Corp. | Oksadiazol aminski spojevi derivati kao inhibitor histonske deacetilaze 6 i farmaceutska kompozicija koja sadrži iste |
| ES2975689T3 (es) | 2016-01-29 | 2024-07-11 | Ono Pharmaceutical Co | Derivado de tetrahidronaftaleno |
| LT3426243T (lt) | 2016-03-09 | 2021-08-10 | Raze Therapeutics, Inc. | 3-fosfogliceratdehidrogenazės inhibitoriai ir jų panaudojimas |
| US20200321533A1 (en) | 2016-05-24 | 2020-10-08 | President And Fellows Of Harvard College | Compounds for organic light emitting diode materials |
| MX385718B (es) | 2016-06-13 | 2025-03-18 | Gilead Sciences Inc | Compuestos moduladores de fxr (nr1h4). |
| CA3252823A1 (en) | 2016-06-13 | 2025-02-25 | Gilead Sciences, Inc. | Substituted tert-butyl-3-(2-chloro-phenyl)-3-hydroxyazetidine-1-carboxylate compounds |
| WO2018106818A1 (en) | 2016-12-07 | 2018-06-14 | Kura Oncology, Inc. | Methods of promoting beta cell proliferation |
| AR110988A1 (es) | 2017-02-21 | 2019-05-22 | Sanofi Sa | Compuestos de azetidina como moduladores de gpr119 para el tratamiento de la diabetes, la obesidad, la dislipidemia y trastornos relacionados |
| EP3666770A4 (en) | 2017-08-07 | 2021-04-07 | Joint Stock Company "Biocad" | NEW HETEROCYCLIC COMPOUNDS AS CDK8 / 19 INHIBITORS |
| CA3087886A1 (en) | 2018-01-19 | 2019-07-25 | Idorsia Pharmaceuticals Ltd | C5a receptor modulators |
| US10695334B2 (en) | 2018-08-16 | 2020-06-30 | Boehringer Ingelheim International Gmbh | Heteroaromatic carboxamide derivatives as plasma kallikrein inhibitors |
| CA3109090A1 (en) | 2018-08-17 | 2020-02-20 | F. Hoffmann-La Roche Ag | Diagnostic and therapeutic methods for the treatment of breast cancer |
| JPWO2020071550A1 (ja) | 2018-10-04 | 2021-09-24 | 京都薬品工業株式会社 | Ｃｄｋ８阻害剤およびその用途 |
| KR102659859B1 (ko) | 2018-10-30 | 2024-04-25 | 길리애드 사이언시즈, 인코포레이티드 | 알파4β7 인테그린의 억제를 위한 화합물 |
| CN111484479B (zh) | 2019-01-25 | 2023-06-13 | 四川科伦博泰生物医药股份有限公司 | 氮杂环化合物、包含其的药物组合物及其制备方法和用途 |
| CA3143280A1 (en) | 2019-07-03 | 2021-01-07 | F. Hoffmann-La Roche Ag | Heterocyclic monoacylglycerol lipase (magl) inhibitors |
| CN114302873A (zh) | 2019-08-20 | 2022-04-08 | 小野药品工业株式会社 | 具有s1p5受体激动活性的化合物的盐和晶形 |
| CN112887914A (zh) * | 2019-11-30 | 2021-06-01 | 深圳市海思半导体有限公司 | 终端间定位方法及装置 |
| CN111704613B (zh) | 2020-06-23 | 2021-07-06 | 中国人民解放军军事科学院军事医学研究院 | 咪唑类衍生物及其作为trpv4抑制剂的用途 |
| EP4267117B1 (en) | 2020-12-23 | 2026-04-08 | Celgene Corporation | Carboxylic acid containing indanyl compounds for the treatment of neurodegenerative diseases |
| US11919879B2 (en) * | 2021-06-16 | 2024-03-05 | Celgene Corporation | Carboxylic acid containing azetidinyl compounds for the treatment of neurodegenerative diseases |
-
2022
- 2022-06-15 US US17/840,876 patent/US11919879B2/en active Active
- 2022-06-15 AR ARP220101582A patent/AR126159A1/es unknown
- 2022-06-15 IL IL308122A patent/IL308122A/en unknown
- 2022-06-15 BR BR112023023420A patent/BR112023023420A2/pt not_active Application Discontinuation
- 2022-06-15 MX MX2023014197A patent/MX2023014197A/es unknown
- 2022-06-15 WO PCT/US2022/033523 patent/WO2022266162A1/en not_active Ceased
- 2022-06-15 TW TW111122266A patent/TW202317534A/zh unknown
- 2022-06-15 AU AU2022291768A patent/AU2022291768A1/en active Pending
- 2022-06-15 JP JP2023577349A patent/JP2024522718A/ja active Pending
- 2022-06-15 EP EP22743647.4A patent/EP4355729A1/en active Pending
- 2022-06-15 KR KR1020247001145A patent/KR20240021883A/ko active Pending
- 2022-06-15 CN CN202280042673.6A patent/CN117500785A/zh active Pending
- 2022-06-15 CA CA3217423A patent/CA3217423A1/en active Pending
-
2024
- 2024-01-25 US US18/422,500 patent/US12552771B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US20230028747A1 (en) | 2023-01-26 |
| EP4355729A1 (en) | 2024-04-24 |
| CN117500785A (zh) | 2024-02-02 |
| CA3217423A1 (en) | 2022-12-22 |
| MX2023014197A (es) | 2024-01-18 |
| US20240270714A1 (en) | 2024-08-15 |
| KR20240021883A (ko) | 2024-02-19 |
| US11919879B2 (en) | 2024-03-05 |
| BR112023023420A2 (pt) | 2024-01-30 |
| AU2022291768A1 (en) | 2023-11-30 |
| WO2022266162A1 (en) | 2022-12-22 |
| IL308122A (en) | 2023-12-01 |
| AR126159A1 (es) | 2023-09-27 |
| US12552771B2 (en) | 2026-02-17 |
| JP2024522718A (ja) | 2024-06-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12552771B2 (en) | Carboxylic acid containing azetidinyl compounds for the treatment of neurodegenerative diseases | |
| EP4267117B1 (en) | Carboxylic acid containing indanyl compounds for the treatment of neurodegenerative diseases | |
| JP7797486B2 (ja) | 新規なｒｈｏ関連タンパク質キナーゼ阻害剤の調製方法およびその調製方法における中間体 | |
| WO2023107563A1 (en) | Carboxylic acid containing indanyl compounds for the treatment of neurodegenerative diseases | |
| JP6611736B2 (ja) | 疼痛に対する多様な活性を有する１−オキサ−４，９−ジアザスピロウンデカン化合物のアルキル誘導体 | |
| AU2023347329A1 (en) | Hexahydro-2h-pyrido[2,1-a]isoquinoline vmat2 inhibitors and methods of use | |
| EP4558480A1 (en) | Compounds for the treatment of neurodegenerative diseases | |
| EA049017B1 (ru) | Содержащие карбоновую кислоту азетидиниловые соединения для лечения нейродегенеративных заболеваний | |
| JP7851934B2 (ja) | 神経変性疾患の治療のための、インダニルを含むカルボン酸化合物 | |
| JP2018531263A6 (ja) | 疼痛に対して活性を有するオキサジアザスピロ化合物 | |
| JP2018531263A (ja) | 疼痛に対して活性を有するオキサジアザスピロ化合物 | |
| CN120379984A (zh) | 作为s1p5的调节剂的杂环化合物 | |
| WO2026059895A1 (en) | Substituted tricyclicheterocyclylsulfonamide derivatives and uses thereof | |
| EP4648851A1 (en) | Substituted (hetero)anilines and their use | |
| WO2024233748A1 (en) | Heteroaryl compounds as ligand directed degraders of irak4 | |
| JP2025530975A (ja) | Ｉｒａｋ３結合剤としての置換イミダゾピラジン化合物 |